Prof Peter Schmid speaks with ecancer at ESMO 2018 in Munich to discuss results from the IMpassion 130 trial of atezolizumab versus placebo in combinations with nab-paclitaxel to treat advanced and metastatic breast cancers.
The experimental combination of PD1 immunotherapy produced improvements in PFS and OS among PD-L1 positive patients, though no benefit was seen in PD-L1 negative patients.
Prof Schmid discusses the tolerability of the drug and the significance of immunotherapy entering breast cancer therapy options, and considers upcoming trials employing checkpoint immunotherapy.
For more on this data, watch his presentation of the trial results at a conference session here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.